MCA-(Ala7, Lys(DNP)9)-Bradykinin

MCA-(Ala7, Lys(DNP)9)-Bradykinin (CPC catalog code AMYD-111) is a synthetic neurodegenerative-disease research peptide in the neurodegenerative category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use MCA-(Ala7, Lys(DNP)9)-Bradykinin as a reference standard in neurodegenerative workflows — for example, aggregation kinetics (tht, ans fluorescence) studies and oligomer- and fibril-mediated toxicity assays. Human clinical evidence is not established.

No. MCA-(Ala7, Lys(DNP)9)-Bradykinin is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a neurodegenerative workflow, MCA-(Ala7, Lys(DNP)9)-Bradykinin is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. ThT fluorescence, AFM / TEM morphology, and neuronal-toxicity readouts (LDH, MTT).

Store lyophilized at −20 °C. Freshly monomerize using HFIP treatment before aggregation experiments. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for AMYD-111. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.